Eli Lilly and Company

Novo Nordisk A/S

The company struck a deal with the White House last week: its obesity drugs will be included in Medicare coverage

Eli Lilly shares hit a record for the first time in more than a year. Are they worth buying?

Developers of diabetes and obesity drugs Eli Lilly and Novo Nordisk have reached agreements with the administration of US President Donald Trump, the two <a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916450">companies</a> <a href="https://investor.lilly.com/news-releases/news-release-details/lilly-and-us-government-agree-expand-access-obesity-medicines">announced on</a> November 6. Under the terms of the deal, the pharmaceutical manufacturers will reduce the prices of their popular drugs.

Lilly and Novo will cut the price of obesity drugs in the US. What will they get in return?

Competition with Eli Lilly and abrupt changes in Novo Nordisk's management are putting pressure on its performance

Ozempic's creator lowered forecasts for the fourth time this year. Should we sell the stock?

Danish Novo Nordisk will release its quarterly report on Nov. 5.

Novo Nordisk's 5 challenges: what's at the center of investment banks' attention 

Viking Therapeutics, Inc.

Shares of biotech company Viking Therapeutics could triple, according to Canaccord Genuity, which in a <a href="https://www.cnbc.com/2025/10/29/biggest-analyst-calls-wednesday-include-nvidia-apple-tesla-datadog.html">coverage initiation</a> called the firm "one of the leading biotech companies in the obesity drug development space," now <a href="https://oninvest.com/article/gde-investoram-iskat-potencial-nyj-hit-na-rynke-preparatov-ot-lisnego-vesa">dominated</a>&nbsp;by Novo Nordisk and Eli Lilly.

Canaccord initiates on obesity drugmaker Viking with 'buy,' sees 200% upside

JPMorgan Chase & Co.

Stryker Corporation

Mastercard Incorporated

Marsh & McLennan Companies, Inc.

Analysts chose companies from a variety of sectors outside of technology

It's not just technology: Morningstar named five popular stocks with top U.S. funds

The retail price of Ozempic, which Trump has called a "weight-loss drug," is about $1,000 for a one-month course

Trump has promised to cut the price of Ozempic to $150. Novo Nordisk and Eli Lilly shares fell

The Coca-Cola Company

Chewy, Inc.

Steve Cohen, founder of hedge fund Point72 Asset Management, believes the current upturn in the markets looks unreliable. He estimates the likelihood of a recession at nearly 45%, and he says indexes could yet return to April lows. "We're all somewhat dependent on news right now, and that's a tricky way to manage money," the investor says.

Cohen's Shield: 10 stocks the Point72 founder uses to protect his portfolio from overheating

Novo Nordisk's Ozempic has shown to reduce the risk of heart attack, stroke and death in patients with diabetes and cardiovascular disease

Novo drug outperformed its Eli Lilly counterpart in trials. Time to buy stock?

Altimmune, Inc.

Terns Pharmaceuticals, Inc.

Following the meteoric success of Novo Nordisk and Eli Lilly’s semaglutide-based weight-loss injections, the obesity and metabolic disease treatment sector has drawn heightened investor attention. Since Ozempic was <a href="https://www.prnewswire.com/news-releases/novo-nordisk-receives-fda-approval-of-ozempic-semaglutide-injection-for-the-treatment-of-adults-with-type-2-diabetes-300567052.html">approved</a>&nbsp;in December 2017, Novo Nordisk’s stock has gained 125%, pushing its <a href="https://companiesmarketcap.com/novo-nordisk/marketcap/">market capitalization</a> to $252 billion. Eli Lilly, after launching <a href="https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-Zepboundtm-tirzepatide-chronic-weight">Zepbound</a>&nbsp;in November 2023, has seen its share price climb 23% and its <a href="https://companiesmarketcap.com/eli-lilly/marketcap/">market cap</a> reach $681 billion. Morgan Stanley <a href="https://www.morganstanley.com/insights/articles/weight-loss-medication-market-unstoppable-growth#:~:text=Morgan%2520Stanley%2520Research%2520now%2520estimates,about%2520%252415%2520billion%2520in%2520sales">estimates</a>&nbsp;the global market for obesity drugs could exceed $150 billion by 2035.

Small caps that can challenge Novo Nordisk and Eli Lilly in the obesity drug market

While raising the recommendation to "buy", investment bank Berenberg simultaneously lowered the target on Novo securities by 25%

The oldest bank in Germany has bet on Novo Nordisk. How is it better than market favorite Eli Lilly?

The Danish pharma company also lowered its profit forecast for the third time this year